These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 6725657)
1. Topical therapy of alopecia areata with squaric acid dibutylester. Case PC; Mitchell AJ; Swanson NA; Vanderveen EE; Ellis CN; Headington JT J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657 [TBL] [Abstract][Full Text] [Related]
2. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study. Chua SH; Goh CL; Ang CB Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014 [TBL] [Abstract][Full Text] [Related]
3. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies. Morita K; Nakamura M; Nagamachi M; Kishi T; Miyachi Y J Dermatol; 2002 Oct; 29(10):661-4. PubMed ID: 12433000 [TBL] [Abstract][Full Text] [Related]
4. Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester. Happle R; Kalveram KJ; Büchner U; Echternacht-Happle K; Göggelmann W; Summer KH Dermatologica; 1980; 161(5):289-97. PubMed ID: 7439477 [TBL] [Abstract][Full Text] [Related]
5. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients. Orecchia G; Malagoli P; Santagostino L Pediatr Dermatol; 1994 Mar; 11(1):65-8. PubMed ID: 8170854 [TBL] [Abstract][Full Text] [Related]
6. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients. Sakai K; Fukushima S; Mizuhashi S; Jinnin M; Makino T; Inoue Y; Ihn H Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice. Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620 [TBL] [Abstract][Full Text] [Related]
9. Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after an additional follow-up period of 19 months. van der Steen PH; Boezeman JB; Happle R Dermatology; 1992; 184(3):198-201. PubMed ID: 1392112 [TBL] [Abstract][Full Text] [Related]
10. Topical immunotherapy of alopecia areata. A follow-up study. Valsecchi R; Cainelli T; Foiadelli L; Rossi A Acta Derm Venereol; 1986; 66(3):269-72. PubMed ID: 2426909 [TBL] [Abstract][Full Text] [Related]
11. [Pigmentation abnormalities in the course of topical immunotherapy of alopecia areata]. Valsecchi R; Pansera B; Rossi A; Cainelli T G Ital Dermatol Venereol; 1989; 124(1-2):31-2. PubMed ID: 2527809 [TBL] [Abstract][Full Text] [Related]
12. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. Tosti A; Guidetti MS; Bardazzi F; Misciali C J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):199-201. PubMed ID: 8708020 [TBL] [Abstract][Full Text] [Related]
13. Squaric acid sensitization is not required for response in the treatment of alopecia areata. Vedak P; Kroshinsky D J Am Acad Dermatol; 2015 Sep; 73(3):471-6. PubMed ID: 26282797 [TBL] [Abstract][Full Text] [Related]
14. Topical immunotherapy in dermatology. Buckley DA; du Vivier AW Int J Clin Pract; 1999 Mar; 53(2):130-7. PubMed ID: 10344049 [TBL] [Abstract][Full Text] [Related]
15. Squaric acid dibutyl ester for the treatment of alopecia areata: A retrospective evaluation. Losol E; Şentürk N Dermatol Ther; 2021 Jan; 34(1):e14726. PubMed ID: 33377267 [TBL] [Abstract][Full Text] [Related]